{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Titan Pharmaceuticals, Inc.
Is Titan Pharmaceuticals, Inc. overvalued or undervalued?
As of August 11, 2022, Titan Pharmaceuticals, Inc. is considered overvalued with a negative financial outlook, reflected in its high Price to Book Value of 2.26, a ROE of -224.24%, and concerning EV ratios, despite a year-to-date stock return of 36.50%.
Is Titan Pharmaceuticals, Inc. technically bullish or bearish?
As of June 11, 2025, Titan Pharmaceuticals, Inc. shows a mildly bullish trend supported by positive MACD and moving averages, despite some mixed signals from Bollinger Bands and OBV.
Who are in the management team of Titan Pharmaceuticals, Inc.?
As of March 2022, Titan Pharmaceuticals, Inc. is led by Dr. Marc Rubin as Executive Chairman and CEO, and Dr. Katherine DeVarney as President and COO, with several independent directors on the board.
What does Titan Pharmaceuticals, Inc. do?
Titan Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing therapeutics for medical disorders. As of March 2025, it has a market cap of $4.02 million and reported a net profit loss of $1 million.
How big is Titan Pharmaceuticals, Inc.?
As of Jun 18, Titan Pharmaceuticals, Inc. has a market capitalization of 4.02 million, with net sales of 0.00 million and a net profit of -4.20 million for the latest four quarters ending in March 2025. As of December 2024, shareholder's funds were 2.44 million and total assets were 2.92 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
